Clinical Trials Logo

Chronic Hepatitis C Infection clinical trials

View clinical trials related to Chronic Hepatitis C Infection.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02932293 Withdrawn - Clinical trials for Chronic Hepatitis C Infection

Triple Combination DAAs for Treating HCV GT1b Subjects

Start date: December 2016
Phase: Phase 2
Study type: Interventional

There is only one kind of treatment (simeprevir 150 mg + sofosbuvir 400 mg+daclatasvir 60 mg) in this study but the treatment duration may be different depending on patients' response to the antiviral therapy and whether patients have liver cirrhosis. If patients have no cirrhosis and the HCV viral load on day 2 is <500 IU/ml, patients will receive sofosbuvir, daclatasvir and simeprevir for 3 weeks, otherwise the treatment duration is 4 weeks. If patients have cirrhosis and the HCV viral load on day 2 is <500 IU/ml, patients will receive sofosbuvir, daclatasvir and simeprevir for 6 weeks, otherwise the treatment duration will be 8 weeks.

NCT ID: NCT00682591 Withdrawn - Clinical trials for Chronic Hepatitis C Infection

Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy

Start date: July 2008
Phase: N/A
Study type: Observational

Prospective, longitudinal multi-center study performed in 15 participating substitution centers in Germany. Aims: - Primary objective: To compare the impact of the different substitution drugs (methadone, buprenorphine, and suboxone) on the neurocognitive, emotional, and quality-of-life-related tolerability in opioid dependent patients under HCV treatment. - Secondary objective: To investigate if IFN therapy impairs efficacy (with respect to e.g. retention rates, concomitant drug use and in particular neurocognitive function) and tolerability of agonist maintenance treatment with methadone, buprenorphine, or suboxone